The 16,17-Double Bond Is Needed for Irreversible Inhibition of Human Cytochrome P45017α by Abiraterone (17-(3-Pyridyl)androsta-5,16-dien-3β-ol) and Related Steroidal Inhibitors
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Abiraterone (17-(3-pyridyl)androsta-5,16-dien-3beta-ol, 1) is a potent inhibitor (IC50 4 nM for hydroxylase) of human cytochrome P45017alpha. To assist in studies of the role of the 16,17-double bond in its mechanism of action, the novel 17alpha-(4-pyridyl)androst-5-en-3beta-ol (5) and 17beta-(3-pyridyl)-16,17alpha-epoxy-5alpha-androst-3beta-ol (6) were synthesized. 3beta-Acetoxyetienic acid was converted in three steps into 5 via photolysis of the thiohydroxamic ester 8. Oxidation of an appropriate 16,17-unsaturated precursor (21) with CrO3-pyridine afforded the acetate (23) of 6. Inhibition of the enzyme by 1, the similarly potent 5,6-reduced analogue 19 (IC50 5 nM), and the 4, 16-dien-3-one 26 (IC50 3 nM) and by the less potent (IC50 13 nM) 3,5, 16-triene 25 is slow to occur but is enhanced by preincubation of the inhibitor with the enzyme. Inhibition following preincubation with these compounds is not lessened by dialysis for 24 h, implying irreversible binding to the enzyme. In contrast under these conditions the still potent (IC50 27 nM) 17alpha-(4-pyridyl)androst-5-en-3beta-ol (5) showed partial reversal after 5 h of dialysis and complete reversal of inhibition after 24 h. This behavior was also shown by the less potent 16,17-reduced 3-pyridyl compounds 3 and 24. Further, in contrast to the compounds (1, 19, 25, 26) with the 16,17-double bond, the inhibition of the enzymic reaction was not enhanced by preincubation either with 5 or with the 17beta-pyridyl analogues 3, 4, and 24 which also lack this structural feature. The results show that the 16,17-double bond is necessary for irreversible binding of these pyridyl steroids to cytochrome P45017alpha. However oxidation to an epoxide is probably not involved since epoxide 6 was only a moderately potent inhibitor (IC50 260 nM).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Abiraterone acetate, a prodrug of abiraterone, is a selective inhibitor of androgen biosynthesis that potently blocks cytochrome P450 c17 (CYP17), a critical enzyme in testosterone synthesis, thereby blocking androgen synthesis by the adrenal glands and testes and within the prostate tumor.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [14]
Citations
Cites
Radical chemistry associated with the thiocarbonyl group
Crich, D., & Quintero, L. (1989) · Chemical Reviews · doi:10.1021/cr00097a001 · Cited by 496
Recent Developments of Free-Radical Substitutions of Heteroaromatic Bases
Minisci, F., Vismara, E., & Fontana, F. (1989) · HETEROCYCLES · doi:10.3987/rev-88-sr1 · Cited by 452
Potter, G. A., Barrie, S. E., Jarman, M., & Rowlands, M. G. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00013a022 · Cited by 379
Self-citationPharmacology of novel steroidal inhibitors of cytochrome P45017 (17α-hydroxylase/C17–20 lyase)
Barrie, S. E., Potter, G. A., Goddard, P. M., Haynes, B. P., Dowsett, M., & Jarman, M. (1994) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(94)90131-7 · Cited by 253
Self-citationWong, C. H., & Matos, J. R. (1985) · The Journal of Organic Chemistry · doi:10.1021/jo00211a046 · Cited by 69
Angelastro, M. R., Laughlin, M. E., Schatzman, G. L., Bey, P., & Blohm, T. R. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)90854-1 · Cited by 46
Rollin, P. (1986) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)84938-2 · Cited by 40
Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P45017α inhibitors
Barrie, S. E., Haynes, B. P., Potter, G. A., Chan, F. C. Y., Goddard, P. M., Dowsett, M., & Jarman, M. (1997) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(96)00225-7 · Cited by 37
Self-citationKurihara, T., Sugizaki, M., Kime, I., Wada, M., & Mitsunobu, O. (1981) · Bulletin of the Chemical Society of Japan · doi:10.1246/bcsj.54.2107 · Cited by 35
Alcohol inversion of 17β-steroids
Dodge, J. A., & Lugar, C. W. (1996) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(95)00559-c · Cited by 33
Research works printed but not linked: 9
- Rowlands M. G., 1996, J. Med. Chem., 38, 4197
- Chan F. C. Y., 1996, J. Med. Chem., 39, 3323
- Burke D. F. Ph.D., 1994, University of London
- Sato T., 1995, J. Org. Chem., 60, 2629
- Garreg P., 1982, J. Chem Soc., Perkin Trans. 1, 681, 683
- Barton D. H. R., 1986, Tetrahedron Lett., 27, 1330
- Catagnino E., 1986, Tetrahedron Lett., 27, 6338
- Bo T., 1996, Synthesis, 324, 326
- Pearson A. J., 1985, J. Chem. Soc., Perkin Trans. 1, 267, 273
Cited by
Items 101–153 of 153
Guengerich, F. P., McCarty, K. D., Chapman, J. G., & Tateishi, Y. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100969 · Cited by 13
“What is not clear about some of the previous work with abiraterone is why some studies reported time-dependent inhibition (30, 45), which was clearly not seen in our own work (Figs.”
ResultSequencing Systemic Therapies in Metastatic Castration-Resistant Prostate Cancer
Liu, J. J., & Zhang, J. (2013) · Cancer Control · doi:10.1177/107327481302000306 · Cited by 14
Gajula, S. N. R., Reddy, G. N., Dannarm, S. R., & Sonti, R. (2020) · Bioanalysis · doi:10.4155/bio-2020-0242 · Cited by 13
Yu, K., Gao, B., Liu, Z., & Ding, H. (2016) · Chemical Communications · doi:10.1039/c6cc00930a · Cited by 11
Potential impact of combined inhibition of 3α-oxidoreductases and 5α-reductases on prostate cancer
Fiandalo, M. V., Gewirth, D. T., & Mohler, J. L. (2018) · Asian journal of urology · doi:10.1016/j.ajur.2018.09.002 · Cited by 10
“The CYP17A1 inhibitor, abiraterone, impairs both the 17a-hydroxylase and 17,20-lyase activities of the enzyme, thus blocking adrenal androgen synthesis [28,29].”
BackgroundSynthesis of Some Steroidal Oxazolines
Woelfling, J., Mernyák, E., Sebők, M., & Schneider, G. (2001) · Collection of Czechoslovak Chemical Communications · doi:10.1135/cccc20011831 · Cited by 10
Gasperoni, L., Giunta, E. F., Montanari, D., Masini, C., & Giorgi, U. D. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2353749 · Cited by 12
“AA is a selective inhibitor of the cytochrome P450 17 enzyme (CYP17) and acts as an androgen biosynthesis inhibitor because CYP17 is a crucial enzyme in androgen biosynthesis in testes, adrenals, prostate tissues including prostate tumor cells (Figure 1) [17–19].”
BackgroundSchneider, G., Görbe, T., Mernyák, E., Woelfling, J., Holczbauer, T., Czugler, M., Sohár, P., Minorics, R., & Zupkó, I. (2015) · Steroids · doi:10.1016/j.steroids.2015.02.018 · Cited by 8
The Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer
Hu, Q., & Hartmann, R. W. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-396521-9.00011-5 · Cited by 10
Photocatalytic Minisci Reaction
Gambarotti, C., Melone, L., Punta, C., & Raffaini, G. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800070-0.00013-x · Cited by 8
Cirillo, P. F., Caccavale, A., & DeLuna, A. (2020) · Journal of Chemical Education · doi:10.1021/acs.jchemed.0c00991 · Cited by 7
Neighboring group participation
Szájli, Á., Woelfling, J., Mernyák, E., Minorics, R., Márki, Á., Falkay, G., & Schneider, G. (2005) · Steroids · doi:10.1016/j.steroids.2005.09.008 · Cited by 7
Kiss, A., Herman, B. E., Görbe, T., Mernyák, E., Molnár, B., Woelfling, J., Szécsi, M., & Schneider, G. (2018) · Steroids · doi:10.1016/j.steroids.2018.03.006 · Cited by 7
Sequencing Strategies in the New Treatment Landscape of Prostate Cancer
Caffo, O., Maines, F., Kinspergher, S., Veccia, A., & Messina, C. G. M. (2019) · Future Oncology · doi:10.2217/fon-2019-0190 · Cited by 9
Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic
Salvador, J. A. R., Vania, M., & Silvestre, S. (2013) · InTech eBooks · doi:10.5772/52290 · Cited by 10
Paliwal, A., Alam, A., Sharma, P. A., Jain, S., & Dhoundiyal, S. (2024) · Current Cancer Therapy Reviews · doi:10.2174/0115733947288355240305080236 · Cited by 9
Bastrakov, M. A., Fedorenko, A. K., Starosotnikov, A. M., & Shakhnes, A. K. (2021) · Molecules · doi:10.3390/molecules26185547 · Cited by 6
Cicero, G., Luca, R. D., Blasi, L., Pepe, A., Pavone, C., Simonato, A., & Dieli, F. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000549 · Cited by 6
Chetia, A., Saikia, A. K., Saikia, C. J., & Boruah, R. C. (2003) · Tetrahedron Letters · doi:10.1016/s0040-4039(03)00324-1 · Cited by 6
SYNTHESIS OF MODIFIED STEROIDS IN THE ANDROSTANE AND ANDROSTENE SERIES
Stéphan, É. (2006) · Organic Preparations and Procedures International · doi:10.1080/00304940609355990 · Cited by 6
Noncanonical Mechanisms to Regulate Nuclear Receptor Signaling
Sadana, P. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.72 · Cited by 6
Caffo, O., Palermo, A., Veccia, A., Maines, F., Chierichetti, F., & Galligioni, E. (2013) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2013.04.021 · Cited by 5
Priya, M. G. R., Manisha, J., Lazar, L. P. M., Rathore, S. S. S., & Solomon, V. R. (2024) · Current Computer - Aided Drug Design · doi:10.2174/0115734099283410240406064042 · Cited by 6
Stevanović, M. Z., Bekić, S. S., Petri, E. T., Ćelić, A. S., Jakimov, D., Sakač, M. N., & Kuzminac, I. Z. (2024) · Future Medicinal Chemistry · doi:10.4155/fmc-2024-0039 · Cited by 4
Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer
Goyal, J., & Antonarakis, E. S. (2013) · Clinical Medicine Insights Urology · doi:10.4137/cmu.s8337 · Cited by 5
Hu, J., Aprikian, A. G., Saleh, R., & Dragomir, A. (2022) · Current Oncology · doi:10.3390/curroncol29110680 · Cited by 5
“Specifically, ABI is a selective irreversible inhibitor of CYP17, an enzyme necessary for the production of extragonadal and testicular androgens [11].”
BackgroundSingh, S., Singh, P. K., Sachan, K., Kumar, M., & Bhardwaj, P. (2023) · Current Computer - Aided Drug Design · doi:10.2174/0115734099260187230921073932 · Cited by 5
Metabolic and toxicological considerations of newly approved prostate cancer drugs
Tsao, C., Liaw, B. C.-H., Yee, T., Galsky, M. D., & Oh, W. K. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.789019 · Cited by 6
“2 Mechanism of action Abiraterone acetate is a selective, irreversible inhibitor of cytochrome (CYP) 17, which catalyzes two essential steps required for androgen biosynthesis [3].”
BackgroundHormonal therapy in metastatic prostate cancer: current perspectives and controversies
Garg, M., Singh, V., Kumar, M., & Sankhwar, S. (2013) · Oncology Reviews · doi:10.4081/oncol.2013.e6 · Cited by 3
Takács, E., Berente, Z., Háda, V., Mahó, S., Kollár, L., & Skoda‐Földes, R. (2009) · Tetrahedron · doi:10.1016/j.tet.2009.04.036 · Cited by 3
The role of abiraterone in the management of metastatic castration-resistant prostate cancer
Rawlinson, A., Mohammed, A. A., Beatty, J. D., Bell, R., & Miller, M. A. W. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.12 · Cited by 3
Simultaneous Autophagy and Androgen Receptor Inhibition in a Prostate Cancer Xenograft Model
Salemi, S., Kranzbühler, B., Baumgartner, V., Breitenmoser, L., Kuzmanov, A., Lehner, F., & Eberli, D. (2024) · Cancers · doi:10.3390/cancers16193261 · Cited by 2
“Abiraterone acetate (Abi), a prodrug of abiraterone, robustly inhibits 17-hydroxylase/C17 (CYP17), a crucial enzyme in testosterone production [4].”
BackgroundAbiraterone for the Treatment of mCRPC
Zafeiriou, Z., Mehra, N., & Bono, J. S. D. (2016) · Springer eBooks · doi:10.1007/978-3-319-31341-2_9 · Cited by 2
COVALENT ENZYME INHIBITION IN DRUG DISCOVERY AND DEVELOPMENT
Mehdi, S. (2013) · Wiley eBooks · doi:10.1002/9781118739907.ch3 · Cited by 2
An Overview of In Silico Drug Discovery with Emphasis on Cancer
Biswas, S., & Bagchi, A. (2022) · Handbook of Oxidative Stress in Cancer: Therapeutic Aspects · doi:10.1007/978-981-16-5422-0_137 · Cited by 1
Ramezani, S. R., Mojra, A., & Tafazzoli‐Shadpour, M. (2024) · National and International Iranian Conference on Biomedical Engineering (ICBME) · doi:10.1109/icbme64381.2024.10895809 · Cited by 2
Yanai, Y., Kosaka, T., Hongo, H., & Oya, M. (2019) · IJU Case Reports · doi:10.1002/iju5.12073 · Cited by 1
Yang, Y. C. (2016) · cIRcle (University of British Columbia) · doi:10.14288/1.0165748 · Cited by 1
Belfort, G. M., Harrison, B. L., & Botella, G. M. (2016) · Wiley eBooks · doi:10.1002/9783527800315.ch6 · Cited by 1
Hu, Q. (2010) · Publications of the UdS (Saarland University) · doi:10.22028/d291-22685
Abiraterone acetate for metastatic castration-resistant prostate cancer post-docetaxel
Poppel, H. V., Osanto, S., & Joniau, S. (2012) · Clinical Investigation · doi:10.4155/cli.12.100
Prezioso, D. (2013) · Journal of Steroids & Hormonal Science · doi:10.4172/2157-7536.s5-001
Hormonal Therapy in Metastatic Prostate Cancer
Kordan, Y. (2010) · Türk Üroloji Seminerleri/Turkish Urology Seminars · doi:10.5152/tus.2010.27 · Cited by 1
Dellavedova, T., Reynoso, E. M., Quinteros, L., Raul, N., Ponzano, R., Sarria, J. P., Olmedo, J., & Minuzzi, F. (2017) · Clinical Case Reports and Reviews · doi:10.15761/ccrr.1000318
Jarman, M., Barrie, S. E., & Llera, J. M. (1999) · ChemInform · doi:10.1002/chin.199921191
Self-citationInvestigating the role of amino acid transporter LAT3/SLC43A1 in prostate cancer
Zhang, K. (2019) · The Sydney eScholarship Repository (The University of Sydney) · Cited by 1
An Overview of In Silico Drug Discovery with Emphasis on Cancer
Biswas, S., & Bagchi, A. (2021) · Handbook of Oxidative Stress in Cancer: Therapeutic Aspects · doi:10.1007/978-981-16-1247-3_137-1
Iwata, M., 健一郎, 堤., & 寧, 原. (2015) · Folia Pharmacologica Japonica · doi:10.1254/fpj.145.260
Novel and Latest Computational and Development of Anticancer Cancer
Patnala, K., Fernandez, M., & Malla, R. R. (2022) · Onco Therapeutics · doi:10.1615/oncotherap.2022044866
Investigating the Usage of Abiraterone in African American Men with Metastatic Prostate Cancer
Ibilibor, C., Jones, M., Tomaszewski, J. J., Ginzburg, S., Correa, A. F., Uzzo, R. G., Smaldone, M. C., Danella, J. F., Guzzo, T. J., Lee, D. Y., et al. (2025) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-025-02533-3
BindingDB (2010) · UC San Diego · doi:10.7270/q2222tk7
Testosteron im Management des metastasierten Prostatakarzinoms
Wolff, J. M., & Schmid, H. (2015) · Der Urologe · doi:10.1007/s00120-015-3813-4
Metadata
- Authors
- Jarman, M., Barrie, S. E., & Llera, J. M.
- Affiliations
- Institute of Cancer Research (GB)
- ORCID
- Jarman, Michael
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1998-12-01
- Volume
- 41
- Issue
- 27
- Pages
- 5375-5381
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2110171529
- Cited by
- 151
- References
- 16
- Citations by year
- 2025: 2 · 2024: 6 · 2023: 5 · 2022: 5 · 2021: 9 · 2020: 6 · 2019: 8 · 2018: 5 · 2017: 5 · 2016: 15 · 2015: 9 · 2014: 7 · 2013: 16 · 2012: 11
- FWCI
- 0.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Steroid Chemistry and Biochemistry
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- abiraterone, irreversible enzyme inhibition, structure-activity relationship, androgen production
- MeSH terms
- Androstanols, Androstenes, Androstenols, Enzyme Inhibitors, Humans, Kinetics, Male, Pyridines, Steroid 17-alpha-Hydroxylase, Structure-Activity Relationship, Testis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.